Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Revance Therapeutics (RVNC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 680,248
  • Shares Outstanding, K 44,029
  • Annual Sales, $ 3,730 K
  • Annual Income, $ -142,570 K
  • 60-Month Beta 0.85
  • Price/Sales 183.84
  • Price/Cash Flow N/A
  • Price/Book 3.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.85
  • Number of Estimates 6
  • High Estimate -0.77
  • Low Estimate -0.95
  • Prior Year -0.97
  • Growth Rate Est. (year over year) +12.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.07 +6.17%
on 03/18/19
18.15 -11.85%
on 02/20/19
-1.69 (-9.55%)
since 02/15/19
3-Month
15.07 +6.17%
on 03/18/19
20.83 -23.19%
on 01/07/19
-3.04 (-15.97%)
since 12/18/18
52-Week
15.07 +6.17%
on 03/18/19
34.20 -53.22%
on 04/19/18
-15.00 (-48.39%)
since 03/16/18

Most Recent Stories

More News
Revance Releases Fourth Quarter and Full Year 2018 Results

---On track to complete BLA submission with U.S. FDA for glabellar lines indication in the first half of 2019-

RVNC : 16.00 (+3.56%)
Tandem Diabetes Care, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Revance Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 at...

TNDM : 71.31 (-2.52%)
RVNC : 16.00 (+3.56%)
Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that...

RVNC : 16.00 (+3.56%)
CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the appointment of Phyllis Gardner,...

COB-U.VN : 5.000 (+4.17%)
CWBR : 3.47 (-8.68%)
RVNC : 16.00 (+3.56%)
PARNF : 0.2600 (-13.33%)
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines

Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.

EOLS : 23.85 (-3.95%)
AGN : 150.84 (-0.27%)
LLY : 125.24 (+1.05%)
RVNC : 16.00 (+3.56%)
Revance Therapeu Falls 3.37% on Heavy Volume: Watch For Potential Rebound

Revance Therapeu (NASDAQ:RVNC) traded in a range yesterday that spanned from a low of $16.93 to a high of $17.78. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of...

RVNC : 16.00 (+3.56%)
SmarTrend Watching for Potential Pullback in Shares of Revance Therapeu After 4.06% Gain

Revance Therapeu (NASDAQ:RVNC) traded in a range yesterday that spanned from a low of $17.68 to a high of $17.76. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high...

RVNC : 16.00 (+3.56%)
Investor Expectations to Drive Momentum within International Paper, Gray Television, Nielsen Holdings Plc, e.l.f. Beauty, NIC, and Revance Therapeutics -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of International Paper Company...

GTN : 22.28 (-0.71%)
IP : 46.23 (+1.58%)
EGOV : 17.28 (+1.59%)
NLSN : 27.26 (+1.15%)
ELF : 9.33 (+0.97%)
RVNC : 16.00 (+3.56%)
Revance Announces Closing of Public Offering of Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"),...

RVNC : 16.00 (+3.56%)
Best Relative Performance in the Pharmaceuticals Industry Detected in Shares of Pacira Pharmaceu (PCRX , MNK , RVNC , OMER , AERI )

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

MNK : 22.71 (+3.84%)
PCRX : 39.42 (+2.07%)
RVNC : 16.00 (+3.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade RVNC with:

Business Summary

Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS' peptide technology, which when combined...

See More

Key Turning Points

2nd Resistance Point 16.75
1st Resistance Point 16.38
Last Price 16.00
1st Support Level 15.35
2nd Support Level 14.69

See More

52-Week High 34.20
Fibonacci 61.8% 26.89
Fibonacci 50% 24.64
Fibonacci 38.2% 22.38
Last Price 16.00
52-Week Low 15.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar